RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 9
SP 13
OP 14
DO 10.1177/155989771209010
UL http://mdc.sagepub.com/content/12/9/13.abstract
AB Data from a Phase 2b study suggest that baricitinib, an oral JAK1/JAK2 inhibitor, is an efficacious treatment for rheumatoid arthritis when used in combination with traditional disease-modifying antirheumatic drugs.